Fulvestrant

Fulvestrant

Chemical Structure

Overview

Fulvestrant, is an antiestrogenic medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with abemaciclib or palbociclib in women with disease progression after endocrine therapy. It is given by injection into a muscle.

Fulvestrant is a selective estrogen receptor degrader (SERD) and was first-in-class to be approved. It works by binding to the estrogen receptor and destabilizing it, causing the cell’s normal protein degradation processes to destroy it.

Key Features

  • Molecular Formula C32H47F5O3S
  • Therapeutic Category Estrogen Receptor Antagonists
  • API Technology High Potent
  • Dose Form Injectable

Use In

  • Breast cancer

    Fulvestrant is used for the treatment of hormone receptor positive metastatic breast cancer or locally advanced unresectable disease in postmenopausal women.

  • Early puberty

    Fulvestrant has been used in the treatment of peripheral precocious puberty in girls with McCune–Albright syndrome.

Open Part Close Part IP BP USP EP
Available Available
Send Inquiry